Toxic megacolon associated with Clostridium difficile infection recurrence: a case report complicated by multiple bacterial infections and successfully treated with oral fidaxomicin

Toxic megacolon associated with Clostridium difficile infection recurrence: a case report complicated by multiple bacterial infections and successfully treated with oral fidaxomicin

Authors

  • Addolorata Masiello U.O.C. Malattie Infettive, A.O.R.N. “S.G. Moscati” Avellino
  • Mario Magliocca U.O.C. Malattie Infettive, A.O.R.N. “S.G. Moscati”, Avellino
  • Giuseppina Dell’Aquila U.O.C. Malattie Infettive, A.O.R.N. “S.G. Moscati”, Avellino
  • Patrizia Maio U.O.C. Malattie Infettive, A.O.R.N. “S.G. Moscati”, Avellino
  • Sergio Giglio U.O.C. Malattie Infettive, A.O.R.N. “S.G. Moscati”, Avellino
  • Nicola Acone U.O.C. Malattie Infettive, A.O.R.N. “S.G. Moscati”, Avellino

DOI:

https://doi.org/10.7175/cmi.v8i1S.957

Keywords:

Toxic megacolon, Clostridium difficile, Fidaxomicin

Abstract

Toxic megacolon is a severe complication of Clostridium difficile infection (CDI) with a high percentage of mortality. The mainstay of treatment is currently represented by medical management, while surgical intervention is indicated in patients not improving after 2-3 days of antibiotic therapy. Generally metronidazole and vancomycin are administered as first-line treatment, but recently several cases of refractory C. difficile have made the treatment of this infection more difficult. Fidaxomicin is a narrow-spectrum oral macrocyclic antibiotic with excellent in vitro activity against C. difficile strains. We report the case of a woman admitted with a diagnosis of toxic megacolon complicating a C. difficile colitis not responding to standard antibiotic therapy.

References

Kazanowski M, Smolarek S, Kinnarney F, et al. Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities-a systematic review. Tech Coloproctol 2014; 18: 223-32; http://dx.doi.org/10.1007/s10151-013-1081-0

To KB, Napolitano LM. Clostridium difficile Infection: Update on diagnosis, epidemiology, and treatment strategies. Surg Infect (Larchmt) 2014; 15: 490-502; http://dx.doi.org/10.1089/sur.2013.186

Zhou FF, Wu S, Klena JD, et al. Clinical characteristics of Clostridium difficile infection in hospitalized patients with antibiotic-associated diarrhea in a university hospital in China. Eur J Clin Microbiol Infect Dis 2014; 33: 1773-9; http://dx.doi.org/10.1007/s10096-014-2132-9

Lee YC, Wang JT, Chen AC, et al. Changing incidence and clinical manifestations of Clostridium difficile-associated diarrhea detected by combination of glutamate dehydrogenase and toxin assay in Northern Taiwan. J Microbiol Immunol Infect 2012; 45: 287-95; http://dx.doi.org/10.1016/j.jmii.2011.12.001

Cober ED, Malani PN. Clostridium difficile infection in the “oldest” old: clinical outcomes in patients aged 80 and older. J Am Geriatr Soc 2009; 57: 659-62; http://dx.doi.org/10.1111/j.1532-5415.2009.02182.x

Vonberg RP, Kuijper EJ, Wilcox MH, et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microb Infect 2008; 14 (S5): 2-20; http://dx.doi.org/10.1111/j.1469-0691.2008.01992.x

Arumilli BR, Koneru P, Fayyaz I. Toxic megacolon from hypervirulent Clostridium difficile infection (ribotype 027) following elective total knee replacement: an emerging challenge in modern health care. BMJ Case Rep 2010; 2010. pii: bcr06.2009.2017; http://dx.doi.org/10.1136/bcr.06.2009.2017

Griniatsos J, Dimitriou N, Tyritzis, et al. Toxic megacolon due to fulminant Clostridium difficile colitis. Acta Gastroenterol Belg 2011; 74: 359-60

Sayedy L, Kothari D, Richards RJ. Toxic megacolon associated Clostridium difficile colitis. World J Gastrointest Endosc 2010; 2: 293-7; http://dx.doi.org/10.4253/wjge.v2.i8.293

McMullen TP, Bailey RJ. Advances in the diagnosis and management of toxic megacolon. Can J Gastroenterol 2005; 19: 163-4

Gerding DN, Muto CA, Owens RC. Treatment of Clostridium difficile Infection. Clin Infect Dis 2008; 46: S32-S42; http://dx.doi.org/10.1086/521861; http://dx.doi.org/10.1086/521860

Cocanour CS. Best strategies in recurrent or persistent Clostridium difficile infection. Surg Infect (Larchmt) 2011; 12: 235-9; http://dx.doi.org/10.1089/sur.2010.080

Bass SN, Bauer SR, Neuner EA, et al. Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection. J Hosp Infect 2013; 85: 22-7; http://dx.doi.org/10.1016/j.jhin.2012.12.019

Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect 2014; 20 Suppl 2: 1-26; http://dx.doi.org/10.1111/1469-0691.12418

O’Horo JC, Jindai K, Kunzer B, et al. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection 2014; 42: 43-59; http://dx.doi.org/10.1007/s15010-013-0496-x

DuPont HL. Challenges and opportunities in the management of Clostridium difficile infection. Expert Rev Gastroenterol Hepatol 2014; 8: 863-74; http://dx.doi.org/10.1586/17474124.2014.939630

Chahine EB, Sucher AJ, Mantei K. Fidaxomicin: A novel macrolide antibiotic for Clostridium difficile Infection. Consult Pharm 2014; 29: 614-24; http://dx.doi.org/10.4140/TCP.n.2014.614

Scott LJ. Fidaxomicin: a review of its use in patients with Clostridium difficile infection. Drugs 2013; 73: 1733-47; http://dx.doi.org/10.1007/s40265-013-0134-z

Esmaily-Fard A, Tverdek FP, Crowther DM, et al. The use of fidaxomicin for treatment of relapsed Clostridium difficile Infections in patients with cancer. Pharmacotherapy 2014; 34: 1220-5; http://dx.doi.org/10.1002/phar.1479

Nathwani D, Cornely OA, Van Engen AK, et al. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother 2014; 69: 2901-12; http://dx.doi.org/10.1093/jac/dku257

Cornely OA, Nathwani D, Ivanescu C, et al. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 2014; 69: 2892-900; http://dx.doi.org/10.1093/jac/dku261

Downloads

Published

2014-12-12

Issue

Vol. 8 No. 1S (2014)

Section

Case report

License

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)